Our Global Partners

As EXCITE International grows, we continue to strengthen our relationships with global strategic partners who represent regulators, payers, health systems, patients, expert end-users and scientists (“stakeholders”). Through this global partnership, EXCITE International offers companies and its stakeholders an unparalleled collaborative approach to selecting, evaluating and adopting impactful new health technologies across the full continuum from proof-of-concept to protocol development.

Our Partner-Specific Approach:


We have built strong relationships with payers and health systems whose pivotal involvement occurs through active participation on the Payers’ Advisory Committee. Representatives on the Payers’ Advisory Committee are drawn from Blue Cross Blue Shield Association, Centre for Medicare and Medicaid, Aetna/CVS, Anthem, Providence Health Care and Bright Health Care. These senior policy decision makers do not represent their host organizations but bring their experience at the interface between evidence and policy decision making to EXCITE programs.

EXCITE has an Agreement with the Harvard associated Baim Institute of Clinical Research, through which it conducts clinical trials following completion of EXCITE Early Technology Reviews requested by companies.

Industry is also well represented through our close association with AdvaMed and the Medical Devices Manufacturers Association (MDMA). Our close working relationship with the Medical Devices Innovation Consortium (MDIC) is focused on patient engagement discussions have been occurred with the Yale Medical School CORE program and the Patient Centered Research Foundation to develop access patient outcomes data for technology evaluation purposes. EXCITE includes expectations of the FDA in all its offerings through information shared with EXCITE by companies in their engagement with the FDA.


An early version of the EXCITE concept was initially piloted in Ontario starting in 2012 with funding from the Ontario government. EXCITE enjoys a collaboration with Ozmosis Research Inc and MedTech Canada in addition to an associate working on behalf of EXCITE to profile opportunities to Canadian industry.


In 2018, EXCITE International established a formal relationship with Norway through an MOU with Norway HealthTech, which has been responsible for profiling opportunities to Norwegian companies to access the U.S. market through EXCITE programs. A member of the Norwegian Ministry of Health sits on the Payers Advisory Committee.


In 2018, EXCITE International established a formal relationship with the Netherlands through an agreement with Radboud University Medical Center (Radboud umc). Through this relationship, Netherlands-based companies have accessed EXCITE programs and EXCITE has used Radboud to provide health economic analysis as part of the services offered to its client companies. This relationship has continued to grow through the recently developed Hii Netherlands initiative which is exploring a meaningful relationship with EXCITE to continue the excellent collaboration to date. Members of Hii Netherlands sit on the EXCITE Scientific Collaboration.

United Kingdom

EXCITE enjoys its interaction with the National Health Service NHS through representation on our Payers Advisory Committee the Association of British HealthTech Industries through representation on the EXCITE Advisory Council and the presence of clinical trial experts from Oxford and Glasgow Universities. On the Scientific Collaboration.

     Insperanto is very pleased to collaborate with EXCITE International for the purpose of helping tech companies meet engage with an expert panel of decision makers in the market to better understand evidentiary needs of decision makers before spending money on development and IP. Thus, bringing the best innovation opportunities to the health sector.

Work with us. EXCITE International can assist you in facilitating multi-jurisdictional clinical trials through its partnership with government, clinical experts, methodology centres and health system decision makers.